The Clinical Trial Application (CTA) to initiate the company's Phase 2b study, with its candidate drug, AP1189, in patients with newly diagnosed rheumatoid arthritis (RA) has been approved in Moldova. The aim is to start recruitment of patients as soon as the study sites has been initiated in SepAlready a…